Bacterial strains, the compositions thereof and use thereof in a method for the treatment of vitamin D deficiency, and disorders associated therewith
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12472214-B2
Publication Date
2025-11-18
Expiration Date
Abstract
The present invention relates to bacterial strains for use in the treatment of vitamin D deficiency and/or insufficiency and/or diseases, symptoms and/or disorders associated thereto. Furthermore, the present invention relates to compositions comprising at least one of said bacterial strains and at least one vitamin D, preferably vitamin D3, and to the use thereof in the treatment of said vitamin D deficiency and/or insufficiency and/or diseases, symptoms or disorders associated thereto.
Core Innovation
The invention relates to a method of treating a patient having vitamin D deficiency and/or insufficiency (hypovitaminosis D) and/or a disease, symptom and/or disorder associated with said vitamin D deficiency, comprising administering to the patient a bacterial strain belonging to Lactobacillus paracasei, reclassified Lacticaseibacillus paracasei, selected from specific deposited strains including Lactobacillus paracasei DG deposited under CNCM 1-1572 and Lactobacillus paracasei LPC-SOl deposited under DSM 26760, or mixtures thereof. The core approach is to increase vitamin D levels in the subject.
The document links this increase to vitamin D biology concepts including 25(OH)D and the vitamin D receptor (VDR). It further describes that the selected Lactobacillus paracasei strains can modulate intestinal VDR expression, and that co-administration with vitamin D is presented as potentially synergistic.
The document also addresses formulations and therapeutic/prophylactic conceptually targeted conditions associated with vitamin D deficiency, including categories of diseases and disorders. In vitro and in vivo findings are described: improved choleciferol emulsification/dissolution in water for Lactobacillus paracasei DG CNCM 1-1572 versus other strains, and murine findings where daily co-administration with vitamin D3 is reported to increase serum 25(OH)D and affect ileal VDR receptor mRNA expression.
Claims Coverage
The independent claim covers one therapeutic method in which administering specific deposited Lactobacillus paracasei (reclassified Lacticaseibacillus paracasei) strains, or mixtures, to increase vitamin D levels is applied to treating patients with vitamin D deficiency/insufficiency (hypovitaminosis D) and/or diseases, symptoms, and/or disorders associated with that deficiency. The dependent claims introduce additional inventive refinements on vitamin D forms, co-administration timing, and restricting associated disorders to specific bone- and mineral-related conditions.
Increasing vitamin D levels with Lactobacillus paracasei strains
A method of treating a patient having vitamin D deficiency and/or insufficiency (or hypovitaminosis D) and/or a disease, symptom and/or disorder associated with said vitamin D deficiency, comprising administering to the patient a bacterial strain belonging to Lactobacillus paracasei (reclassified Lacticaseibacillus paracasei), wherein the bacterial strain belongs to the species Lactobacillus paracasei selected from the group consisting of a strain identified as Lactobacillus paracasei DG deposited at CNCM 1-1572 (Lactobacillus casei DG sub. casei), a strain identified as Lactobacillus paracasei LPC-SOl deposited at DSM 26760, and mixtures thereof, thereby increasing vitamin D levels in the subject.
Co-administration timing with vitamin D
The method further includes administering the bacterial strain together with vitamin D, with the dosing of the bacterial strain and vitamin D occurring simultaneously or with a delayed timing.
Targeting vitamin D forms (vitamin D3 and/or vitamin D2)
The method is applied to vitamin D deficiency specifically comprising deficiency and/or insufficiency of vitamin D3 (cholecalciferol) and/or vitamin D2 (ergocalciferol).
Restricting associated disorders to bone- and mineral-related conditions
The disease, symptom and/or disorder is selected from bone- and mineral-related conditions.
Co-administration together with vitamin D3
The method includes administering the bacterial strain together with vitamin D3.
Overall claim coverage centers on administering specific deposited Lactobacillus paracasei (reclassified Lacticaseibacillus paracasei) strains, or mixtures, to increase vitamin D levels in subjects with hypovitaminosis D and/or associated disorders. Refinements specify vitamin D forms (D3 and/or D2), co-administration with vitamin D including simultaneous or delayed timing, a restriction of associated disorders to bone- and mineral-related conditions, and an option where co-administration is together with vitamin D3.
Stated Advantages
Increasing vitamin D levels in the subject.
Potentially synergistic action when co-administered with vitamin D.
Documented Applications
Treating a patient having vitamin D deficiency and/or insufficiency (hypovitaminosis D) and/or a disease, symptom and/or disorder associated with vitamin D deficiency.
Clinical/pediatric use concept described as a double-blind randomized clinical study comparing vitamin D3 alone vs vitamin D3 plus a Lactobacillus paracasei (L. casei DG) probiotic.
Interested in licensing this patent?